• About us
• Contact

Advertisement

Organisation › Details

Valneva Austria GmbH

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell’s vaccine to prevent Japanese Encephalitis is the Company’s first product on the market. The Company’s technology platform includes an antigen-discovery system and human anti-infective monoclonal antibody discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships, including with a number of pharmaceutical companies, with GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Romark. The Company’s pipeline of investigational products includes a Pseudomonas aeruginosa vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase I/II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), a vaccine candidate for Pneumococcus (Phase I) as well as a combination treatment approach for Hepatitis C (Phase II). A vaccine candidate against infections with C. difficile has entered Phase I clinical trials in 2010. In addition, further products focused on infectious diseases are in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol “ICLL” (U.S. level one ADR symbol “INRLY”). *

 

	Start	1998-01-01 established
	End	2013-10-17 renamed before
	Group	Valneva (Group)
	Predecessor	Intercell Austria AG
	Industry	vaccine
	Person	Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
	Person 2	Kandera, Reinhard (Hookipa Biotech 201704– CFO before Valneva CFO + Intercell CFO + Deutsche Bank AG)
	Region	Wien (Vienna)
	Country	Austria
	Street	3 Campus-Vienna-Biocenter
	City	1030 Wien
	Tel	+43-1-20620
		Address record changed: 2020-12-02
Basic data	Employees	D: 101 to 500 (2015-09-22)
		* Document for »About Section«:
		Record changed: 2023-08-20

Advertisement

More documents for Valneva (Group)

• [1] Valneva S.E.. (11/10/23). "Press Release: Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
• [2] Valneva S.E.. (11/9/23). "Press Release: Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates". Saint Herblain....
• [3] Valneva S.E.. (11/7/23). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint Herblain....
• [4] Valneva S.E.. (10/25/23). "Press Release: Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment". Saint Herblain....
• [5] Valneva S.E.. (9/25/23). "Press Release: Valneva Announces New Ixiaro Supply Contract with the U.S. Government Worth a Minimum of $32 Million". Saint Herblain....
• [6] NorthX Biologics. (7/3/23). "Press Release: NorthX Biologics, a Leading Nordic Development and Manufacturing Organisation Announces Acquisition of a Biologics Manufacturing Unit from Valneva". Matfors....
• [7] Valneva S.E.. (11/17/22). "Press Release: Valneva Appoints Dipal Patel as Chief Commercial Officer". Saint-Herblain....
• [8] Valneva S.E.. (10/4/22). "Press Release: Valneva Announces Closing of Upsized €102.9 Million Global Offering". Saint-Herblain....
• [9] Valneva S.E.. (8/18/22). "Press Release: Valneva Provides Update on Ixiaro Supply Contract with U.S. Department of Defense". Saint-Herblain....
• [10] Valneva S.E.. (8/8/22). "Press Release: Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15". New York, NY & Saint-Herblain....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.